Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,889 people get ACAD articles and Market Currents by email alert.
Get email alerts on ACAD »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference CallMon, Nov 9, 2009
-
Acadia Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptMon, Mar 9, 2009
-
ACADIA Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptWed, Nov 5, 2008
-
ACADIA Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call TranscriptTue, Mar 11, 2008
-
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call TranscriptWed, Mar 5, 2008
-
Acadia Pharmaceuticals Q3 2007 Earnings Call TranscriptMon, Nov 5, 2007
-
Business Wire (Jun 3, 2013)
-
Business Wire (May 29, 2013)
-
at CNBC.com (May 23, 2013)
-
Business Wire (May 20, 2013)
-
Business Wire (May 15, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013Business Wire (Apr 25, 2013)
-
at MarketWatch.com (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 11, 2013)
-
at MarketWatch.com (Apr 9, 2013)
-
at CNBC.com (Apr 4, 2013)
-
at CNBC.com (Mar 22, 2013)
-
at CNBC.com (Mar 18, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Mar 12, 2013)
ACAD vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently are developing a portfolio consisting of four product candidates including our most advanced compound, pimavanserin,... More
-
- View all 2 replies
-
-
-
- View all 0 replies
-
StockConsultant
$ACAD remains strong, continuation breakout watch above 15.12, charts analysis http://bit.ly/11sMPZF - View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
ACADIA Pharmaceuticals ($ACAD) has gained 800% over the last 52-weeks. Steps look like institutional buying. http://yhoo.it/ZjLk0B;c= - View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
-
LATEST REPLIES
-
- View all 2 replies
-
-
-
- View all 5 replies
-
-
-
- View all 1 replies
-
-
Perkins Cove
$ACAD, good trade for those that could trade @7:00am in pre mkt.... http://seekingalpha.com/n/k39t - View all 2 replies
-
Perkins Cove: I saw a low of 10.75, and a high of 12.50. My broker doesn't start until 8:00am, so no position. Be careful who you pick for a broker.
-
Perkins Cove: I understand Scottrade and Fidelity start @ 7:00. Any others...?
-
Brian Nichols
After data $ACAD will have $700 million market cap by end of week. It was significantly undervalued - View all 7 replies
-
-
Brian Nichols: I actually bought @ $5.20, but it's only for a trade. I will probably sell tomorrow and then look 4 a better opportunity n the next 2 months
-
- View all 3 replies
-
-
-
Scott Matusow
I cant buy ACAD now because ATRS is my claim. No way I will sell a single share of it. I just know it will be acquired in the next year. - View all 10 replies
-
-
TDPeterson123: Was just curious - appreciate your consideration. I'm not selling any ATRS. No. Do you advise keeping a "limit" in place, & how long?
-
Scott Matusow
I am looking at Acadia Pharma (ACAD) for this week. like what I see with it. Risky pick as a developmental bio, but has large upside to it. - View all 1 replies
-
